Oruka Therapeutics, Inc. (NASDAQ:ORKA) Stock Has Consensus Price Target of $133.00 According to Brokerages

Oruka Therapeutics, Inc. (NASDAQ:ORKA) has received a consensus recommendation of “Moderate Buy” from the eleven analysts that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and ten have given a buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $133.00.

A number of analysts have recently issued reports on the stock. Mizuho set a $120.00 price target on shares of Oruka Therapeutics in a research report on Thursday, September 3rd. Piper Sandler reissued an “overweight” rating on shares of Oruka Therapeutics in a research report on Wednesday, October 7th. HC Wainwright reaffirmed a “buy” rating on shares of Oruka Therapeutics in a research report on Tuesday, October 27th. Wall Street Zen downgraded Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. Finally, BTIG Research reiterated a “buy” rating and set a $151.00 price target on shares of Oruka Therapeutics in a report on Monday, October 19th.

Insider Activity

In other news, insider Joana Goncalves sold 7,947 shares of the firm’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $92.38, for a total transaction of $734,143.86. Following the transaction, the insider owned 31,771 shares in the company, valued at approximately $2,935,004.98. This trade represents a 20.01% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Arjun Agarwal sold 10,000 shares of the stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $106.66, for a total transaction of $1,066,600.00. Following the transaction, the senior vice president directly owned 15,312 shares in the company, valued at $1,633,177.92. The trade was a 39.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 179,950 shares of company stock worth $16,492,680. 23.49% of the stock is owned by corporate insiders.

Institutional Trading of Oruka Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. acquired a new stake in Oruka Therapeutics during the 2nd quarter worth approximately $474,916,000. Jupiter Topco LLC acquired a new position in shares of Oruka Therapeutics during the 2nd quarter worth approximately $130,968,000. Remedium Capital Partners LLC boosted its holdings in shares of Oruka Therapeutics by 0.9% in the 1st quarter. Remedium Capital Partners LLC now owns 1,565,661 shares of the company’s stock valued at $76,796,000 after buying an additional 13,247 shares during the last quarter. Avidity Partners Management LP grew its stake in shares of Oruka Therapeutics by 15.1% in the first quarter. Avidity Partners Management LP now owns 760,424 shares of the company’s stock valued at $37,299,000 after buying an additional 100,000 shares in the last quarter. Finally, Bank of America Corp DE acquired a new position in Oruka Therapeutics during the second quarter worth $33,578,000. 56.44% of the stock is currently owned by institutional investors and hedge funds.

Oruka Therapeutics Trading Up 1.9%

NASDAQ ORKA opened at $101.41 on Monday. Oruka Therapeutics has a 12 month low of $25.23 and a 12 month high of $115.51. The company’s 50 day simple moving average is $88.16 and its 200 day simple moving average is $69.91.

Oruka Therapeutics (NASDAQ:ORKA) last issued its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). On average, sell-side analysts anticipate that Oruka Therapeutics will post -2.42 EPS for the current fiscal year.

About Oruka Therapeutics

Oruka Therapeutics, Inc (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company is focused on creating treatments that may provide durable disease control while reducing the frequency of administration compared with conventional biologic therapies.

Oruka’s pipeline is centered on engineered monoclonal antibodies that target the interleukin-17 (IL-17) pathway, an important driver of inflammation in conditions such as psoriasis and other autoimmune diseases.